BRIEF-Rocket Pharmaceuticals Updates Registration Path For RP-A501 In Danon Disease

Reuters

Dec 22, 2022

Dec 22 (Reuters) - Rocket Pharmaceuticals Inc :

* ROCKET PHARMACEUTICALS PROVIDES UPDATE ON ANTICIPATED REGISTRATION PATH FOR RP-A501 IN DANON DISEASE FOLLOWING END-OF-PHASE 1 FDA MEETING

* ROCKET PHARMACEUTICALS - TO PURSUE A BIOMARKER-BASED COMPOSITE ENDPOINT FOR A SINGLE ARM, OPEN-LABEL PIVOTAL TRIAL WITH A NATURAL HISTORY COMPARATOR

* ROCKET PHARMACEUTICALS INC - INITIATION OF INITIAL COMPONENT OF GLOBAL STUDY ANTICIPATED IN 1H'23

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2293958822"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2293958822\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2293958822?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-12-22 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2293958822","market":"us","top_or_hot":-1,"title":"BRIEF-Rocket Pharmaceuticals Updates Registration Path For RP-A501 In Danon Disease","media":"Reuters","content":"<html><body><p>Dec 22 (Reuters) - Rocket Pharmaceuticals Inc   :</p><p>   * ROCKET PHARMACEUTICALS PROVIDES UPDATE ON ANTICIPATED REGISTRATION PATH FOR RP-A501 IN DANON DISEASE FOLLOWING END-OF-PHASE 1 FDA MEETING</p><p>   * ROCKET PHARMACEUTICALS - TO PURSUE A BIOMARKER-BASED COMPOSITE ENDPOINT FOR A SINGLE ARM, OPEN-LABEL PIVOTAL TRIAL WITH A NATURAL HISTORY COMPARATOR</p><p>   * ROCKET PHARMACEUTICALS INC - INITIATION OF INITIAL COMPONENT OF GLOBAL STUDY ANTICIPATED IN 1H'23</p><p>Source text for Eikon:    Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rocket Pharmaceuticals Updates Registration Path For RP-A501 In Danon Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rocket Pharmaceuticals Updates Registration Path For RP-A501 In Danon Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-12-22 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Dec 22 (Reuters) - Rocket Pharmaceuticals Inc   :</p><p>   * ROCKET PHARMACEUTICALS PROVIDES UPDATE ON ANTICIPATED REGISTRATION PATH FOR RP-A501 IN DANON DISEASE FOLLOWING END-OF-PHASE 1 FDA MEETING</p><p>   * ROCKET PHARMACEUTICALS - TO PURSUE A BIOMARKER-BASED COMPOSITE ENDPOINT FOR A SINGLE ARM, OPEN-LABEL PIVOTAL TRIAL WITH A NATURAL HISTORY COMPARATOR</p><p>   * ROCKET PHARMACEUTICALS INC - INITIATION OF INITIAL COMPONENT OF GLOBAL STUDY ANTICIPATED IN 1H'23</p><p>Source text for Eikon:    Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCKT","symbol_name":"Rocket Pharmaceuticals, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2293958822","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2293958822","pubTimestamp":1671707159,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 22 (Reuters) - Rocket Pharmaceuticals Inc   :   * ROCKET PHARMACEUTICALS PROVIDES UPDATE ON ANTI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCKT":"Rocket Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"简介-Rocket Pharmaceuticals更新了Danon病中RP-A501的注册路径","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RP":1,"RCKT":0.9},"content_text":"Dec 22 (Reuters) - Rocket Pharmaceuticals Inc   :   * ROCKET PHARMACEUTICALS PROVIDES UPDATE ON ANTICIPATED REGISTRATION PATH FOR RP-A501 IN DANON DISEASE FOLLOWING END-OF-PHASE 1 FDA MEETING   * ROCKET PHARMACEUTICALS - TO PURSUE A BIOMARKER-BASED COMPOSITE ENDPOINT FOR A SINGLE ARM, OPEN-LABEL PIVOTAL TRIAL WITH A NATURAL HISTORY COMPARATOR   * ROCKET PHARMACEUTICALS INC - INITIATION OF INITIAL COMPONENT OF GLOBAL STUDY ANTICIPATED IN 1H'23Source text for Eikon:    Further company coverage:   ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}